Evidence map›Paper›PMID 15899217›Full record

ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2005

[Current status of the prognostic value of molecular markers in patients with colorectal cancer and the prediction of response to adjuvant therapy].

Jose M Fernández-Cebrián, Peter Vorwald Kuborn, Mar Pardo de Lama, Alfonso Sanjuanbenito Dehesa, Manuel Nevado Santos, Pedro A Pacheco Martínez, Beatriz Fernández-Escudero

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jose M Fernández-CebriánUnidad de Cirugía General y Aparato Digestivo, Fundación Hospital Alcorcón, C/Budapest 1, Alcorcón, 28922 Madrid, Spain. jmfernandez@fhalcoron.es
Peter Vorwald Kuborn
Mar Pardo de Lama
Alfonso Sanjuanbenito Dehesa
Manuel Nevado Santos
Pedro A Pacheco Martínez
Beatriz Fernández-Escudero

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer is one of the best studied of all malignant diseases in terms of genetics and/or molecular prognostic factors. These factors, and relationships with prognosis, may have important implications especially in the design of surgical and adjuvant chemo-radiotherapy options. However, the true prognostic significance of all known factors has yet to be realised. We have reviewed the literature with specific focus on the role of molecular markers involved in prognosis and the prediction of response to adjuvant treatment.

Indexed as

ApoptosisBiomarkers, TumorColorectal NeoplasmsCombined Modality TherapyHumansMutationOncogenesPrognosisBiomarkers, Tumor

Identifiers

PMID15899217

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.